Mirati Therapeutics (MRTX) Adds New Director
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced the appointment of Dr. Bruce L.A. Carter to the Company's Board of Directors where he will also serve as a member of the Audit Committee and Compensation Committee, effective immediately.
"It is a privilege to welcome such a respected and accomplished professional to our board of directors," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "Bruce brings a great deal of experience gained as a former CEO and seasoned pharmaceutical executive whose expertise and leadership will make a significant contribution as we aggressively advance our pipeline, including our three clinical stage programs."
"I believe that Mirati will transform the treatment of patients with cancer using drugs that target the very specific genetic changes that drive tumor growth," said Dr. Carter. "Joining the team at this juncture provides a great opportunity to work with respected leaders in oncology drug development and contribute to the Company's growth strategy."
Dr. Carter has extensive governing experience as an executive and leader in the pharmaceutical and biotechnology industries, having served as President and CEO of ZymoGenetics and as Executive Vice President and Chief Scientific Officer of Novo Nordisk. Dr. Carter most recently served as the Executive Chairman of Immune Design Corp. and previously as a director of multiple biotechnology companies, including as non-executive Chairman of the Board of ZymoGenetics when it was sold to Bristol-Myers Squibb in 2010. Dr. Carter currently serves as Board Chairman for Enanta Pharmaceuticals and for Xencor, Inc., and as a director of Dr. Reddy's Laboratories in India.
Dr. Carter is also an Affiliate Professor, Department of Biochemistry at the University of Washington, Seattle, Washington and serves as Board Chair of the Infectious Disease Research Institute in Seattle, Washington and is on the Board of Directors of the TB Alliance. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neogen Corp. (NEOG) Appoints Dr. Dan Kephart as Its Chief Science Officer
- Acxiom's (ACXM) LiveRamp Closes Arbor and Circulate ACquisitions
- Shutterfly (SFLY) Adds Two New Directors
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Related EntitiesZymoGenetics/Bristol-Myers Squibb
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!